In KRAS-mutant SUIT-2 cells, FTH1 knockdown led to significant decreases in cancer cell viability via G2/M cell cycle arrest in vitro as well as tumor growth suppression in the SUIT-2 xenograft model in vivo (Fig. 3). The gene discussed is KRAS; the disease is cancer.